Real-time Pain Monitoring in Fibromyalgia Patients

Pain Clinical Trial

Official title:

Utilization of Real-time Pain Monitoring System (PAMS), ANAPA System, in Patients With Rheumatic Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03571009
• Other study ID #: PAAS in FMS
• Status: Completed
• Phase: N/A
• Start date: December 22, 2015
• Est. completion date: September 21, 2017

Study information

• Verified date: June 2018
• Source: Seoul St. Mary's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to examine whether the pain of fibromyalgia patients can be reduced with utilization of real-time pain monitoring system (PAAS). In this pilot study, adult fibromyalgia patients were randomly assigned to use or to not use PAAS. Changes in the visual analogue scale (VAS) were examined by rheumatologists at baseline and after three months, and correlations between conventional pain VAS or PAAS VAS and clinical parameters (patient global assessment, physician global assessment, fibromyalgia impact questionnaire) were investigated. We also examined if the utilization of PAAS can affect health related quality of life and depression.

Description:

Chronic pain is difficult to treat and is debilitating to patients in various ways, including wide spread suffering, disability, social displacement, and expense. For effective pain management, the first step should be to assess the exact status of the pain. This process may include characterizing the pain, quantifying it as accurately as possible, and analyzing influencing factors. However, it is hard to objectify pain because it is an invisible and subjective. The visual analogue scale (VAS) is widely used to assess the severity of pain. Moreover, current management of chronic pain is based on a patient's recall, which may be inaccurate. It would be ideal if we could manage pain by recording its status on a real-time basis, reflecting the impact of environmental factors. The Pain Assessment and Analysis System (PAAS) has been developed to monitor and record real-time pain. Users are asked to report the type of experienced pain and its severity. Therefore, for user convenience, PAAS can be accessed using a wearable device (Painmeter, LST, Seoul, Korea) that is interlinked with a smartphone mobile application (DrKooB-PAAS, iKooB Inc. Seoul, South Korea). The system records the frequency and severity of pain and can create reports summarizing the pain over the course of various time intervals. In addition, this system also records the time, temperature, humidity, and weather, along with the reported pain, to determine any correlations between the pain and these environmental factors. Fibromyalgia (FMS) is a complex disorder characterized by intractable, widespread pain and somatic symptoms such as insomnia, constipation, diarrhea, and cognitive dysfunction. The exact pathogenesis has yet to be elucidated, but current understandings suggest that disturbances in pain-regulating neurotransmitters are involved. The diagnosis and management of FMS are a challenge for physicians. Its management should combine pharmacological and non-pharmacological approaches, which suggests there are various factors that influence treatment outcomes. To date, tricyclic agents, serotonin norepinephrine reuptake inhibitors, and pregabalin are known to have beneficial effects; however, a substantial number of patients are still suffering from the uncontrolled pain of FMS.

To address the pain in these patients, an appropriate pain monitoring system that can reflect real-time pain severity and frequency and can analyze the pattern of impacting factors can be used to provide effective treatment and to eventually improve patient pain. Therefore, we aimed to investigate the feasibility of a real-time pain monitoring system, the Pain Assessment and Analysis System (PAAS), in patients with FMS in order to evaluate its effect on pain reduction. In addition, we evaluated the correlations between the VAS measured by PAAS and clinical parameters reflecting the disease activity of FMS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 21, 2017
• Est. primary completion date: November 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

• Inclusion Criteria:

19 years of age or older diagnosed with fibromyalgia based on the 2010 American College of Rheumatology preliminary diagnostic criteria for FMS

• Exclusion Criteria:

previously diagnosed with a serious systemic medical illness a medical condition that can affect bodily pain: eg. (1) inflammatory arthritis (2) malignancy

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes
• Pain

Intervention

Device:
• utilization of PAAS
utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ji Hyeon Ju

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Pain visual analogue scale	The pain visual analogue scale (0-10 mm) of the patient is addressed on each visit. Changes in pain visual analogue scale on 3 months visit is evaluated.	3 months after randomization
Secondary	Changes in the dose of medication	To address the dose and the class of the medication	3 months after baseline visit
Secondary	Changes in the disease activity	Fibromyalgia impact questionnaire is used to address the disease activity	3 months after baseline visit
Secondary	Changes in the quality of life	Euro QoL - 5D questionnaire is used to address hearth related quality of life	3 months after baseline visit
Secondary	Changes in the depressive symptoms	Beck's depression index is used to address the severity of depressive symptoms	3 months after baseline visit
Secondary	Correlation of pain visual analogue scale (VAS) by pain assessment analysis system (PAAS) with patient global assessment	correlation between PAAS VAS and patient global assessment (0-10 mm)	1 month after baseline visit
Secondary	Correlation of pain visual analogue scale (VAS) by pain assessment analysis system (PAAS) with disease activity	correlation between PAAS VAS and Fibromyalgia impact questionnaire scores	1 month after baseline visit
Secondary	Correlation of pain visual analogue scale (VAS) by pain assessment analysis system (PAAS) with physician global assessment	correlation between PAAS VAS and physician global assessment (0-10 mm)	1 month after baseline visit